These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Pharmacological and clinical properties of calcimimetics: calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism. Nagano N Pharmacol Ther; 2006 Mar; 109(3):339-65. PubMed ID: 16102839 [TBL] [Abstract][Full Text] [Related]
4. Modulation and action of the calcium-sensing receptor. Drüeke TB Nephrol Dial Transplant; 2004 Aug; 19 Suppl 5():V20-26. PubMed ID: 15284356 [TBL] [Abstract][Full Text] [Related]
5. Calcimimetic agents and secondary hyperparathyroidism: rationale for use and results from clinical trials. Goodman WG Pediatr Nephrol; 2003 Dec; 18(12):1206-10. PubMed ID: 14586685 [TBL] [Abstract][Full Text] [Related]
6. Calcimimetics in the treatment of primary hyperparathyroidism. Antoniucci DM; Shoback D J Bone Miner Res; 2002 Nov; 17 Suppl 2():N141-5. PubMed ID: 12412791 [No Abstract] [Full Text] [Related]
8. [Therapeutic agents for disorders of bone and calcium metabolism. The calcimimetic cinacalcet HCl]. Nakanishi S; Fukagawa M Clin Calcium; 2007 Jan; 17(1):88-92. PubMed ID: 17211098 [TBL] [Abstract][Full Text] [Related]
10. Positive and negative allosteric modulators promote biased signaling at the calcium-sensing receptor. Davey AE; Leach K; Valant C; Conigrave AD; Sexton PM; Christopoulos A Endocrinology; 2012 Mar; 153(3):1232-41. PubMed ID: 22210744 [TBL] [Abstract][Full Text] [Related]
11. The new role of calcimimetics as vasculotropic agents. Al-Aly Z Kidney Int; 2009 Jan; 75(1):9-12. PubMed ID: 19092812 [TBL] [Abstract][Full Text] [Related]
12. The calcium receptor and calcimimetics. Wada M; Nagano N; Nemeth EF Curr Opin Nephrol Hypertens; 1999 Jul; 8(4):429-33. PubMed ID: 10491737 [TBL] [Abstract][Full Text] [Related]
13. [Calcimimetics--a new treatment for hyperparathyroidism?]. Piecha G; Chudek J; Wiecek A Pol Merkur Lekarski; 2005 May; 18(107):581-4. PubMed ID: 16161961 [TBL] [Abstract][Full Text] [Related]
14. [Calcimimmetic and calcilytics: new perspectives of correction of abnormal parathormone (PTH) secretion]. Rybczyńska A; Hoppe A Przegl Lek; 2003; 60(6):418-24. PubMed ID: 14974181 [TBL] [Abstract][Full Text] [Related]
15. Calcimimetic and calcilytic drugs: just for parathyroid cells? Nemeth EF Cell Calcium; 2004 Mar; 35(3):283-9. PubMed ID: 15200152 [TBL] [Abstract][Full Text] [Related]
16. Calcimimetics: a new tool for management of hyperparathyroidism and renal osteodystrophy in patients with chronic kidney disease. Lindberg JS Kidney Int Suppl; 2005 Jun; (95):S33-6. PubMed ID: 15882311 [TBL] [Abstract][Full Text] [Related]
17. Effect of the calcimimetic R-568 [3-(2-chlorophenyl)-N-((1R)-1-(3-methoxyphenyl)ethyl)-1-propanamine] on correcting inactivating mutations in the human calcium-sensing receptor. Lu JY; Yang Y; Gnacadja G; Christopoulos A; Reagan JD J Pharmacol Exp Ther; 2009 Dec; 331(3):775-86. PubMed ID: 19759318 [TBL] [Abstract][Full Text] [Related]
18. Calcimimetics and the treatment of primary and secondary hyperparathyroidism. Joy MS; Kshirsagar AV; Franceschini N Ann Pharmacother; 2004 Nov; 38(11):1871-80. PubMed ID: 15479778 [TBL] [Abstract][Full Text] [Related]